Germline analysis of an international cohort of pediatric diffuse midline glioma patients.

阅读:5
作者:Mateos Marion K, Ajuyah Pamela, Fuentes-Bolanos Noemi, El-Kamand Sam, Barahona Paulette, Altekoester Ann-Kristin, Mayoh Chelsea, Holliday Holly, Liu Jie, Cui Louise, Pfaff Elke, Mackay Alan, Resnick Adam C, Pinese Mark, Lau Loretta M S, Khuong-Quang Dong-Anh, Dias Kimberly, Goudie Catherine, Salkeld Alison, Rokita Jo Lynne, Jones David T W, Juretic Nikoleta, Hayden Elisha, Pfister Stefan M, Kramm Christof M, Blattner-Johnson Mirjam, Jabado Nada, Tsoli Maria, Vittorio Orazio, Mueller Sabine, Guo Yiran, Tucker Katherine, Waszak Sebastian M, Perreault Sebastien, Jones Chris, Wong-Erasmus Marie, Cowley Mark J, Ziegler David S
BACKGROUND: Factors that drive the development of diffuse midline gliomas (DMG) are unknown. Our study aimed to determine the prevalence of pathogenic/likely pathogenic (P/LP) germline variants in pediatric patients with DMG. METHODS: We assembled an international cohort of 252 pediatric patients with DMG, including diffuse intrinsic pontine glioma (n†=†153), with germline whole genome or whole exome sequencing. RESULTS: We identified P/LP germline variants in cancer predisposition genes in 7.5% (19/252) of patients. Tumor profiles differed, with the absence of somatic drivers in the PI3K/mTOR pathway in patients with germline P/LP variants versus those without (P†=†.023). P/LP germline variants were recurrent in homologous recombination (n†=†9; BRCA1, BRCA2, PALB2) and Fanconi anemia genes (n†=†4). Somatic findings established that the germline variants definitively contributed to tumorigenesis in at least 1% of cases. One patient with recurrent DMG and pathogenic germline variants (BRCA2, FANCE) showed a near-complete radiological response to PARP and immune checkpoint inhibition. CONCLUSIONS: Our study determined the prevalence of pathogenic germline variants in pediatric DMG and suggests a role in tumorigenesis for a subset of patients.

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。